Notification of Full Year Results

RNS Number : 7643Q
Alliance Pharma PLC
23 February 2023
 

For immediate release

23 February 2023

 

 

 

 

ALLIANCE PHARMA

("Alliance", "Company" or "Group")

 

Notification of Full Year Results, Analyst Meeting and Webcast

 

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the year ended 31 December 2022 on Tuesday 21 March 2023.

A meeting for analysts will be held at 10.00am on the day of the results at Buchanan, 107 Cheapside, London EC2V 6DN. To register for the meeting, analysts should contact Buchanan at alliancepharma@buchanan.uk.com

A live webcast of the analyst meeting will be accessible via the following link: https://stream.buchanan.uk.com/broadcast/63ed07a0355eac0afbf3fbf4

A recording of the webcast will be made available following the meeting at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

 

alliancepharma@buchanan.uk.com

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Broking: Patrick Robb

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSEDFWEEDSEIE
UK 100

Latest directors dealings